Zacks Investment Research Lowers Genocea Biosciences (GNCA) to Hold

Share on StockTwits

Genocea Biosciences (NASDAQ:GNCA) was downgraded by Zacks Investment Research from a “buy” rating to a “hold” rating in a research note issued to investors on Wednesday, Zacks.com reports.

According to Zacks, “Genocea Biosciences, Inc. is involved in developing vaccines. The company’s proprietary discovery platform consists of AnTigen Lead Acquisition System which designs vaccines that stimulate T cell immunity. Its product portfolio which are in different clinical trials consist of GEN-003, HSV-2 infections, GEN-004 and HSV-2 prophylaxis and malaria. Genocea Biosciences, Inc. is headquartered in Cambridge, Massachusetts. “

Several other equities research analysts have also issued reports on the company. Needham & Company LLC reissued a “buy” rating on shares of Genocea Biosciences in a research note on Friday, March 1st. HC Wainwright set a $5.75 price objective on Genocea Biosciences and gave the company a “buy” rating in a research note on Thursday, February 28th. Finally, ValuEngine raised Genocea Biosciences from a “sell” rating to a “hold” rating in a research note on Wednesday, January 2nd.

Shares of Genocea Biosciences stock traded up $0.02 during trading hours on Wednesday, reaching $0.70. The company had a trading volume of 3,003 shares, compared to its average volume of 411,444. The firm has a market capitalization of $80.05 million, a P/E ratio of -1.57 and a beta of 3.04. Genocea Biosciences has a one year low of $0.28 and a one year high of $1.02. The company has a debt-to-equity ratio of 1.44, a current ratio of 2.52 and a quick ratio of 2.52.

Genocea Biosciences (NASDAQ:GNCA) last posted its quarterly earnings data on Tuesday, April 30th. The biotechnology company reported ($0.15) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.09) by ($0.06). Sell-side analysts expect that Genocea Biosciences will post -0.34 earnings per share for the current fiscal year.

In other news, major shareholder Peter W. Sonsini purchased 9,948,269 shares of the company’s stock in a transaction on Thursday, February 14th. The stock was purchased at an average price of $0.47 per share, with a total value of $4,675,686.43. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Insiders own 2.33% of the company’s stock.

An institutional investor recently raised its position in Genocea Biosciences stock. Renaissance Technologies LLC lifted its stake in Genocea Biosciences Inc (NASDAQ:GNCA) by 71.1% during the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 198,766 shares of the biotechnology company’s stock after buying an additional 82,600 shares during the period. Renaissance Technologies LLC owned approximately 0.23% of Genocea Biosciences worth $155,000 as of its most recent SEC filing. Institutional investors and hedge funds own 42.54% of the company’s stock.

Genocea Biosciences Company Profile

Genocea Biosciences, Inc, a biopharmaceutical company, discovers and develops novel cancer vaccines. The company uses its proprietary discovery platform, ATLAS, to recall a patient's pre-existing CD4+ and CD8+ T cell immune responses to tumor to identify antigens for inclusion in vaccines that are designed to act through T cell (or cellular) immune responses.

Featured Article: What is an investor looking for in an SEC filing?

Get a free copy of the Zacks research report on Genocea Biosciences (GNCA)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Genocea Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genocea Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.